Larotrectinib shows marked responses with NTRK gene fusions, limited response in non-fusion mutations
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall survival of 44.4 months in adult and pediatric patients with advanced cancers and NTRK gene fusions, regardless of cancer type. In contrast, those with other mutations in NTRK that were not gene fusions saw only a 1% overall response rate of median overall survival of just 10.7 months, highlighting the...
Genomic study of brain metastases sheds light on unique features relative to primary tumors
A deep sequencing study of brain metastases from MD Anderson revealed many similarities but also distinct differences relative to the primary...
Phase I clinical trial shows WNT974 in combination with spartalizumab well tolerated for advanced solid tumor patients
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in cancer,...
Study shows naproxen promotes immune activation in Lynch syndrome patients
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory drug, is safe to take daily and activates immune pathways in the colorectal mucosa of people living with Lynch syndrome.
The results were published July 8 in Gut and presented at the AACR Virtual Annual Meeting I (Poster CT111). Lynch syndrome is an inherited condition that increases a person’s...
AACR: Ovarian cancer clinical trial shows effects, safety of upfront immunotherapy and chemotherapy for advanced disease
Results from a clinical trial led by MD Anderson researchers showed that combining the immunotherapy checkpoint inhibitor drug durvalumab...
Ovarian cancer analysis identifies potential treatment biomarkers
MD Anderson researchers have identified potential biomarkers for the response of high-grade serous ovarian cancers (HGSC) to surgical resection...